MARKET

BSGM

BSGM

BIOSIG TECHNOLOG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.490
-0.150
-3.23%
Closed 16:00 12/04 EST
OPEN
4.630
PREV CLOSE
4.640
HIGH
4.714
LOW
4.420
VOLUME
295.80K
TURNOVER
--
52 WEEK HIGH
12.43
52 WEEK LOW
2.360
MARKET CAP
135.82M
P/E (TTM)
-2.0116
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BioSig to Highlight PURE EP(TM) System at the Benzinga Global Small Cap Conference
EQNX::TICKER_START (NASDAQ:BSGM), EQNX::TICKER_END
GlobeNewswire · 1d ago
Insider Buys BioSig Technologies Stock
 
Benzinga · 2d ago
BioSigs PURE EP System to Support Live Patient Cases during EPLive 2020
Company’s flagship product to be featured in live patient cases broadcast from the Texas Cardiac Arrhythmia Institute on December 3-4, 2020Westport, CT, Nov. 30, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that its flagship technology would be featured in several live cases broadcast during EPLive 2020, the fifth international symposium on complex arrhythmias.EPLive is an intensive, two-day educational meeting for practicing clinical cardiac electrophysiologists, electrophysiology fellows, and general cardiologists interested in treating complex cardiac arrhythmias. A total of 21 live and 13 recorded cases will broadcast from the new, state-of-the-art Electrophysiology Center at St. David’s Medical Center in Austin, TX, with expert commentary and will serve as the primary teaching tool.The PURE EP™ System will be highlighted in several patient cases conducted live by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., Executive Medical Director of TCAI and EPLive course director, and Joseph Gallinghouse, M.D. “We are thrilled to be included in EPLive, a very unique physician education event, and we appreciate all the effort that went into making this important conference a reality amidst the global pandemic. We are grateful to Dr. Natale and his colleagues at TCAI for the outstanding support they continue to provide to our team and to the entire faculty of EPLive for their dedication to improving patient outcomes through the introduction of sophisticated educational tools and techniques for the benefit of the global physician audience,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.“More than 350 cases have been performed with the PURE EP™ System so far, and we are thrilled to see the value that additional physiologic information can provide across all types of cardiac arrhythmias. We are honored to be part of EPLive, and we look forward to continuing this exciting journey with the entire EP community,” commented Olivier Chaudoir, Sr. Director of Marketing at BioSig Technologies, Inc.Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center was the first clinical installation site for the evaluation of BioSig’s PURE EP™ System. To date, more than 350 patient cases have been completed with the PURE EP™ System by 25 electrophysiologists across several clinical sites. For more information about the event, please visit www.ep-live.com.  About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company's first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.  CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
GlobeNewswire · 4d ago
Insider Buys BioSig Technologies Shares
 
Benzinga · 11/19 16:32
BioSig to Host Business Update Conference Call on November 18, 2020
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call on November 18, 2020, at 4:15 PM ET. Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. will review highlights from the Company's third quarter of 2020 and discuss corporate initiatives, including ongoing PURE EP(TM) System installations and commercialization outlook.
GlobeNewswire · 11/12 19:11
BioSig to Host Business Update Conference Call on November 18, 2020
GlobeNewswire · 11/12 19:11
Is BioSig Technologies (NASDAQ:BSGM) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 11/12 10:56
BioSig Announces Completion of PURE EP(TM) System Installation at New Medical Center
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its PURE EP(TM) System and started conducting patient cases at Deborah Heart and Lung Center in Browns Mills, New Jersey.
GlobeNewswire · 10/29 18:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BSGM. Analyze the recent business situations of BIOSIG TECHNOLOG through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BSGM stock price target is 12.75 with a high estimate of 13.00 and a low estimate of 12.50.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 5.67M
% Owned: 18.73%
Shares Outstanding: 30.25M
TypeInstitutionsShares
Increased
27
521.24K
New
27
-483.43K
Decreased
16
236.80K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.17%
Healthcare Equipment & Supplies
+1.33%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Kenneth Londoner
Chief Financial Officer
Steven Chaussy
Vice President/Director of Sales
John Kowalski
Vice President/Director of Investor Relations
Andrew Ballou
Vice President
Julie Stephenson
Director of Marketing
Olivier Chaudoir
Other
Manasi Patwardhan
Lead Director/Independent Director
Jeffrey O'Donnell
Director
Anthony Zook
Independent Director
Andrew Filler
Independent Director
Donald Foley
Independent Director
Patrick Gallagher
Independent Director
Samuel Navarro
Independent Director
Martha Pease
Independent Director
David Weild
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BSGM
BioSig Technologies, Inc. is a commercial-stage medical device company. The Company is commercializing biomedical signal processing technology platform to extract information from physiologic signals. The Company focuses on providing intracardiac signal information to electrophysiologists during electrophysiology (EP) studies and cardiac catheter ablation procedures for atrial fibrillation (AF) and ventricular tachycardia (VT). The Company is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The PURE EP System is a signal acquisition and processing technology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of BioSig Technologies Inc stock information, including NASDAQ:BSGM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BSGM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BSGM stock methods without spending real money on the virtual paper trading platform.